There are only two differences between the between the 4/18/23 slide set and the previous version (dated 2/7/23):
• Slide 12 has minor changes about competing RSV drug candidates, mainly that the Ark Bio (China) fusion inhibitor, AK-059 is under review by China’s FDA (https://arkbiosciences.com/en_2022n/114 ).
• Slide 22 has an additional bullet point noting that EDP-235 has an FDA Fast Track designation.
Note: ENTA’s partial monetization of the Mavyret royalty stream on 4/25/23 is too recent to be incorporated in the slide set.